APOE4 is the strongest genetic risk factor for Alzheimer’s disease (AD). Pre-symptomatic APOE4 carriers have developed neurovascular deficits decades before amyloid beta (Aβ) aggregation. Here we show that with Rapamycin treatment for 16 weeks, pre-symptomatic APOE4 mice had restored cerebral blood flow (CBF) and attenuated anxiety, compared to those of APOE3 mice. The CBF restorations were particularly significant in female mice or those with APP transgene. As Rapamycin and MRI and are readily to be used in humans, the findings may provide valuable information for future clinical trials to prevent AD for APOE4 carriers.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords